Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 17/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.92 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.92 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.92 |
| ▸ | TSPO | P30536 | 1/20 | 0.92 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.92 |
| ▸ | HRH1 | P35367 | 1/20 | 0.92 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.92 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.92 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.92 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.92 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiotropium SCHEMBL15129612 | 0.99 | CHRM3 (0.94) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL21483687 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL27894301 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL28716206 | 0.98 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL433959 | 0.98 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL29206611 | 0.98 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL28707361 | 0.98 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL19471214 | 0.98 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL2231775 | 0.98 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL27726355 | 0.98 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2067779-B9 | Tiotropium salts, method for their production and medicinal formulas containing them | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | claimed |
| WO-2013107434-A2 | NEW POLYMORPHOUS FORMS OF TIOTROPIUM IODIDE AND A METHOD OF THEIR PREPARATION | ZENTIVA, K.S. (CZ) | 2013-07-25 | — | — | WO | claimed |
| EP-2067779-B1 | Tiotropium salts, method for their production and medicinal formulas containing them | BOEHRINGER INGELHEIM INT (DE) | 2013-04-24 | — | — | EP | claimed |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-17 | — | — | US | claimed |
| US-20050131007-A1 | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-16 | — | — | US | claimed |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | claimed |
| EP-2682099-B1 | Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists | ARVEN ILAC SANAYI VE TICARET AS (TR) | 2020-09-02 | — | — | EP | disclosed |
| EP-3430011-A2 | A NEW FORM OF ACTIVE AGENT | Sima Patent Ve Lisanslama Hizmetleri Ltd. STI (TR) | 2019-01-23 | — | — | EP | disclosed |
| EP-3414243-A1 | CRYSTALLINE FORM OF TIOTROPIUM BROMIDE ANHYDRATE | Sima Patent Ve Lisanslama Hizmetleri Ltd. STI (TR) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017138896-A1 | CRYSTALLINE FORM OF TIOTROPIUM BROMIDE ANHYDRATE | SIMA PATENT VE LISANSLAMA HIZMETLERI LTD. ŞTI (TR) | 2017-08-17 | — | — | WO | disclosed |
| US-20150150802-A1 | DRY POWDER INHALER COMPOSITIONS COMPRISING LONG ACTING MUSCARINIC ANTAGONISTS | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2015-06-04 | — | — | US | disclosed |
| CN-102964344-B | Novel tiotropium salts, pharmaceutical formulations containing the same, and application thereof | BOEHRINGER INGELHEIM INT | 2014-12-31 | — | — | CN | disclosed |
| CN-101648950-B | Tiotropium salts, pharmaceutical composition and uses thereof | BOEHRINGER INGELHEIM INT | 2014-05-07 | — | — | CN | disclosed |
| WO-2013107434-A2 | NEW POLYMORPHOUS FORMS OF TIOTROPIUM IODIDE AND A METHOD OF THEIR PREPARATION | ZENTIVA, K.S. (CZ) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013107434-A2 | NEW POLYMORPHOUS FORMS OF TIOTROPIUM IODIDE AND A METHOD OF THEIR PREPARATION | ZENTIVA, K.S. (CZ) | 2013-07-25 | — | — | WO | disclosed |
| CN-102964344-A | Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same | BOEHRINGER INGELHEIM INT | 2013-03-13 | — | — | CN | disclosed |
| CN-1875020-B | Novel tiotropium salts, method for the production thereof and pharmaceutical preparations thereof | BOEHRINGER INGELHEIM INT | 2010-04-28 | — | — | CN | disclosed |
| CN-101648950-A | Tiotropium salts, pharmaceutical composition and uses thereof | BOEHRINGER INGELHEIM INT DE | 2010-02-17 | — | — | CN | disclosed |
| US-20050131007-A1 | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-16 | — | — | US | disclosed |
| US-20050096341-A1 | Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096341-A1 | Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof | ADRB3, ADRB1, ADRB2 | CHRM3 6/4885CHRM2 23/4885CHRM1 35/4885 |
| US-20050131007-A1 | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | CHRM3, ADRB3, CHRNA5 | CHRM3 1/4885CHRM2 26/4885CHRM1 32/4885 |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | ADRB3, ADRB1, HSD3B1 | CHRM3 8/4885CHRM2 44/4885CHRM1 62/4885 |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | ADRB3, ADRB1, CHRM3 | CHRM3 3/4885CHRM2 32/4885CHRM1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.